Download ebooks file Translational biotechnology : a journey from laboratory to clinics. 1st edition

Page 1


Translational Biotechnology : A Journey from Laboratory to Clinics. 1st Edition Hasija

https://ebookmass.com/product/translationalbiotechnology-a-journey-from-laboratory-toclinics-1st-edition-hasija/ Download more ebook from https://ebookmass.com

More products digital (pdf, epub, mobi) instant download maybe you interests ...

The Journey from Music Student to Teacher: A Professional Approach 1st Edition, (Ebook PDF)

https://ebookmass.com/product/the-journey-from-music-student-toteacher-a-professional-approach-1st-edition-ebook-pdf/

Introduction to Petroleum Biotechnology 1st Edition

James G. Speight

https://ebookmass.com/product/introduction-to-petroleumbiotechnology-1st-edition-james-g-speight/

Old Testament Today, 2nd Edition – Ebook PDF Version: A Journey from Ancient Context to – Ebook PDF Version

https://ebookmass.com/product/old-testament-today-2nd-editionebook-pdf-version-a-journey-from-ancient-context-to-ebook-pdfversion/

Chemical Projects Scale Up: How to go from Laboratory to Commercial Joe M. Bonem

https://ebookmass.com/product/chemical-projects-scale-up-how-togo-from-laboratory-to-commercial-joe-m-bonem/

Environmental Metabolomics: Applications in field and laboratory studies to understand from exposome to metabolome 1st Edition

https://ebookmass.com/product/environmental-metabolomicsapplications-in-field-and-laboratory-studies-to-understand-fromexposome-to-metabolome-1st-edition-diana-alvarez-munoz-editor/

Jordan's Journey 1st Edition Quinn

https://ebookmass.com/product/jordans-journey-1st-edition-quinn/

How to Get Your PhD : A Handbook for the Journey 1st Edition

https://ebookmass.com/product/how-to-get-your-phd-a-handbook-forthe-journey-1st-edition-gavin-brown/

The Enterprise Linux Administrator: Journey to a New Linux Career 1st Edition Kenneth

https://ebookmass.com/product/the-enterprise-linux-administratorjourney-to-a-new-linux-career-1st-edition-kenneth-hitchcock/

Research ethics in behavior analysis : from laboratory to clinic and classroom

https://ebookmass.com/product/research-ethics-in-behavioranalysis-from-laboratory-to-clinic-and-classroom-david-j-cox/

TRANSLATIONALBIOTECHNOLOGY

Thispageintentionallyleftblank

TRANSLATIONAL BIOTECHNOLOGY

AJourneyfromLaboratorytoClinics

AcademicPressisanimprintofElsevier

125LondonWall,LondonEC2Y5AS,UnitedKingdom

525BStreet,Suite1650,SanDiego,CA92101,UnitedStates

50HampshireStreet,5thFloor,Cambridge,MA02139,UnitedStates

TheBoulevard,LangfordLane,Kidlington,OxfordOX51GB,UnitedKingdom

Copyright©2021ElsevierInc.Allrightsreserved.

Nopartofthispublicationmaybereproducedortransmittedinanyformorbyanymeans,electronicormechanical, includingphotocopying,recording,oranyinformationstorageandretrievalsystem,withoutpermissioninwritingfromthe publisher.Detailsonhowtoseekpermission,furtherinformationaboutthePublisher’spermissionspoliciesandour arrangementswithorganizationssuchastheCopyrightClearanceCenterandtheCopyrightLicensingAgency,canbefound atourwebsite: www.elsevier.com/permissions

ThisbookandtheindividualcontributionscontainedinitareprotectedundercopyrightbythePublisher(otherthanasmay benotedherein).

Notices

Knowledgeandbestpracticeinthisfieldareconstantlychanging.Asnewresearchandexperiencebroadenour understanding,changesinresearchmethods,professionalpractices,ormedicaltreatmentmaybecomenecessary.

Practitionersandresearchersmustalwaysrelyontheirownexperienceandknowledgeinevaluatingandusingany information,methods,compounds,orexperimentsdescribedherein.Inusingsuchinformationormethodstheyshouldbe mindfuloftheirownsafetyandthesafetyofothers,includingpartiesforwhomtheyhaveaprofessionalresponsibility.

Tothefullestextentofthelaw,neitherthePublishernortheauthors,contributors,oreditors,assumeanyliabilityforany injuryand/ordamagetopersonsorpropertyasamatterofproductsliability,negligenceorotherwise,orfromanyuseor operationofanymethods,products,instructions,orideascontainedinthematerialherein.

BritishLibraryCataloguing-in-PublicationData

AcataloguerecordforthisbookisavailablefromtheBritishLibrary LibraryofCongressCataloging-in-PublicationData

AcatalogrecordforthisbookisavailablefromtheLibraryofCongress

ISBN:978-0-12-821972-0

ForInformationonallAcademicPresspublications visitourwebsiteat https://www.elsevier.com/books-and-journals

Publisher: StacyMasucci

Senior AcquisitionsEditor: RafaelE.Teixeira

EditorialProjectManager: MonaZahir

ProductionProjectManager: NiranjanBhaskaran

CoverDesigner: VictoriaPearson

TypesetbyMPSLimited,Chennai,India

Contents

Listofcontributorsxi

Prefacexiii 1

Introductiontotranslational biotechnology

1Translationalbiotechnology: Atransitionfrombasic biologytoevidence-based research3

DebleenaGuin,SaritaThakran,PoojaSingh,S.Ramachandran, YashaHasijaandRitushreeKukreti

1.1Introduction4

1.1.1Backgroundandemergenceofthe field4

1.2Thephasesoftranslationalresearch5

1.3Challengestosolutions6

1.4Applications9

1.4.1Drugdevelopment12

1.4.2Nanomedicine16

1.4.3Genetherapy17

1.4.4Precisionmedicineandbiomarker development19

1.4.5Microbialengineeringfor bio-therapeutics19

1.4.6Applicationofbigdataand translationalbioinformatics19

1.5Conclusionandfuturedirections21

1.6Highlights21 Acknowledgment22 Conflictofinterest22 References22

2

Biotherapeutics

2Biotechnology-basedtherapeutics27

RavichandranVijayaAbinayaandPragasamViswanathan

2.1Introduction28

2.2Humangenetherapy29

2.2.1Somaticcellgenetherapy30

2.2.2Germlinegenetherapy30

2.2.3Genetransfersystem30

2.2.4Gene-editingtechnology33

2.2.5Ethicalissue34

2.3Stemcelltherapy34

2.3.1Sourcesofstemcells35

2.3.2Benefitsofstemcelltherapyinvarious disorder36

2.3.3Challengesandproblems37

2.4Nanomedicine37

2.4.1Nanotherapeuticapplications37

2.4.2Tissueengineering39

2.4.3Nanoimaging40

2.5Drugdesigninganddelivery40

2.5.1Rationaldrugdesign41

2.5.2Computer-aideddrugdesign41

2.5.3Drugdelivery44

2.6Recombinanttherapeuticproteinsand vaccines44

2.6.1Recombinantprotein44

2.6.2Expressionsystem44

2.6.3Recombinantproteinasatreatment46

2.6.4Recombinantvaccine47

2.7Conclusionandfutureapplications48 Acknowledgments48 Conflictsofinterest48

Author’scontribution48 References49

3Advancedbiotechnology-based therapeutics53

SrividhyaRavichandranandGauravVerma

3.1Introduction54

3.2Technologiesthatleadtothediscoveryof therapy55

3.2.1Genomeeditingtechnologies55

3.2.2Roleofnanomedicineindrug discoveryapproaches56

3.2.3Antibody drugconjugates58

3.3Moleculardiagnostics60

3.3.1Translationalbioinformatics62

3.3.2Organoids—toolsfordisease models63

3.4Cell-basedtherapy65

3.5Nanotechnologyanditsusesin biomedicine67

3.6Genome-scalemetabolicmodeling68

3.7Criticalprocessesintheflowfrombasic sciencetopracticalapplicationintheclinic viaclinicaltrialsandtranslationalstudies69

3.8Majorpitfallsintranslationalresearch70

3.9Advancementindevices,biologics,andvaccines asanintroductiontobiotechnologyproducts thatarebeingusedintherapy72

3.10Conclusionandsummary74 References74

3

Pathwayandtargetdiscovery

4Humaninvitrodiseasemodelstoaid pathwayandtargetdiscoveryfor neurologicaldisorders81

BhavanaMuralidharan

4.1Introduction82

4.2Generationofhumandiseasemodelsusing iPSCs/patientfibroblasts83

4.2.1Directeddifferentiationintoneural cells84

4.2.2Directdifferentiationintoneurons/ glia86

4.2.3Directlineagereprogramming/ transdifferentiationintoneurons88

4.3Modelingneurodevelopmentaldisorders88 3.1Rettsyndrome88

4.3.2FragileXsyndrome89

4.3.3Autismspectrumdisorders89

4.3.4Schizophrenia90

4.4Modelingneurodegenerativediseases91 4.4.1Amyotrophiclateralsclerosis91

4.4.2Alzheimer’sdisease92

4.4.3Parkinson’sdisease93

4.5Cerebralorganoidsandthefutureofhuman invitrodiseasemodeling93

4.6Frombenchtobedside—identificationof pathwaysanddrugtargetsfordesigning therapies95

4.7Futureperspectives97

Keyworddefinitions97

Acknowledgments98

References98

5Importanceoftargetedtherapiesin acutemyeloidleukemia107

5.1Introduction107

5.1.1Conventionaltherapyforacutemyeloid leukemia108

5.1.2Significanceoftargetdiscovery108

5.2Approachesintargetdiscovery109

5.2.1Systemsapproach110

5.2.2Molecularapproach111

5.3Acutemyeloidleukemia targetedtherapiesin clinics117

5.3.1BCL-2inhibitors117

5.3.2Isocitratedehydrogenaseinhibitors117

5.3.3PML-RARα targetedtherapy118

5.3.4TargetingFLT3-mutatedacutemyeloid leukemia:frombenchtobedside(acase study)119

5.4Hurdlesandemergingtargetedtherapies120

5.5Conclusion125

Acknowledgments125 References126

4 Noveltherapeuticmodalities

6Biologicaltherapeuticmodalities137 MunishChhabra

6.1Introductiontobiologicaltherapeutic modalities137

6.2Historyofclassicalmodalities139

6.3Newmodalities140

6.3.1Smallmolecules140

6.3.2Nucleicacidtherapeutics142

6.3.3Therapeuticproteins143

6.3.4Antibodies145

6.3.5Cell-basedimmunotherapies148

6.3.6Stemcells150

6.3.7Phagetherapies151

6.3.8Microbiome-basedtherapeutics153

6.4Futureofbiologicaltherapeutics154

6.5Casestudy—bio-therapeuticmodalitiesin COVID-19treatment155

6.6Conclusion156 References160

7ThejourneyofnoncodingRNAfrom benchtoclinic165

RavindreshChhabra

7.1Introduction165

7.1.1NoncodingRNAsandtheir classification165

7.1.2InsiliconcRNApredictiontools166

7.1.3Screeningandcharacterizationof ncRNAs167

7.1.4SmallnoncodingRNAs (miRNAsandsiRNAs)167

7.1.5LongnoncodingRNAs181

7.2PatentlandscapeofnoncodingRNA187

7.3Bottlenecksintheuseofnoncoding RNAsasbiomarkers/therapeutics189

7.4Conclusionsandfutureperspectives191 References192

8Peptide-basedhydrogelsforbiomedical applications203

DebikaDattaandNitinChaudhary

8.1Introduction203

8.2Peptide-basedhydrogelators204

8.2.1 β-Sheetformingpeptides204

8.2.2 α-Helicalpeptides214

8.3Biomedicalapplications215

8.3.1Therapeuticdelivery216

8.3.2Scaffoldforregenerativemedicine218

8.3.3Wounddressing219

8.3.4Antimicrobialagents220

8.4Conclusion,limitations,andfuture directions221 References223

9Bispecificantibodies:Apromising entrantincancerimmunotherapy233

9.1Introduction234

9.2Evolutionofbispecificantibodies234

9.2.1Differentformatsofbispecific antibodies236

9.2.2Mechanismofaction238

9.3Productionofbispecificantibodies243

9.3.1Hybridhybridoma(quadroma technology)243

9.3.2Knob-into-holeapproach243

9.3.3CrossMabapproach244

9.3.4Chemicalconjugation244

9.4Biomarkersinimmunotherapyataglance246

9.4.1Biomarkersforbreastcancer246

9.4.2Biomarkersforprostatecancer247

9.4.3Biomarkersforcheckpointblockade immunotherapy248

9.5Engineeringoftherapeuticprotein248

9.5.1Bindingaffinityenhancement249

9.5.2Immunogenicityminimization249

9.5.3Stabilityenhancementand half-lifeextension250

9.6Marketanalysis:past,presentandfuture250

9.7Futurechallengesandopportunities254

9.8Conclusion255

References255

10Emergingtherapeuticmodalitiesagainst malaria267

SureshKumarChalapareddy,AndaleebSajid,MritunjaySaxena, KritiArora,RajanGuhaandGunjanArora

10.1Introduction267

10.2Heme-detoxificationdrugs268

10.3DrugstargetingDNAorprotein synthesis270

10.4Drugstargetingmembranetransporters271

10.5Naturalproducts272

10.6Protein-basedmalariavaccines273

10.7Nucleicacidvaccinesforthenewera273

10.7.1DNA-basedvaccines274

10.7.2RNA-basedvaccines277

10.8Biologicaltherapeutics277

10.9Conclusion278 References279

5

Healthcarebioinformatics

11Translationalbioinformatics: Anintroduction289

11.1Introduction289

11.2Theeraofomicsandbigdata:datamining andbiomedicaldataintegration292

11.2.1Dataacquisitionand warehousing292

11.2.2Dataintegration293

11.2.3Datamining294

11.3TBIinbiomarkerdiscovery297

11.4Computer-aideddrugdiscovery299

11.5Artificialintelligence-basedapproachin TBI300

11.5.1Complexdiseaseanalysisusing ML301

11.5.2IllustriousexamplesofMLin translationalresearch302

11.6TheimplicationofTBIinprecision medicine304

11.6.1Data-drivenprecisionmedicine initiatives305

11.6.2Futureprospectsoftransitional bioinformaticsinpersonalized medicine305

11.7Conclusion306 References307

12Pharmacodynamicbiomarkerfor HepatocellularcarcinomaC: Model-basedevaluationfor pharmacokinetic pharmacodynamic responsesofdrug311

12.1Hepatocellularcarcinoma312

12.1.1Possibleriskfactorsofhepatocellular carcinoma312

12.1.2Stagesofhepatocellular carcinoma314

12.1.3Challengesintherapeuticand medicinaldrugtreatmentfor hepatocellularcarcinoma316

12.2Pharmacokineticandpharmacodynamic profiles(PK PD)316

12.2.1Pharmacokineticprofile(PK)316

12.2.2Pharmacodynamics(PD)316

12.3Pharmacokineticandpharmacodynamic models317

12.3.1Compartmentalmodels317

12.3.2Directpharmacokineticand pharmacodynamicmodels318

12.3.3Indirectpharmacokineticand pharmacodynamicmodels319

12.4Advantagesofpharmacokineticand pharmacodynamicmodeling319

12.5Developmentofpharmacodynamic(PD) biomarkerinhepatocellularcarcinoma320

12.5.1Proteomicapproachforidentification ofpharmacodynamicbiomarkers321

12.5.2TherapeuticoutcomeusingPD biomarker322

12.6Pharmacokineticandpharmacodynamicdrug responses323

12.7Conclusions323 References324

6 Biologicalsystemsengineering

13Systembiologyandsynthetic biology329

RichaNayak,RajkumarChakrabortyandYashaHasija

13.1Introduction329

13.2Systembiology331

13.2.1Centralprinciplesofscientific approachestobiologysystems332

13.2.2Fieldsintherapeuticapplications systembiology333

13.3Syntheticbiology336

13.3.1Roleofsyntheticbiologyin understandingdisease mechanisms337

13.3.2Syntheticbiologyindrugdiscovery, development,anddelivery339

13.3.3Roleofsyntheticbiologyin personalizedmedicine340

13.3.4Regulationandethicalconsiderations ofsyntheticbiology340

13.4Conclusion341 References342 7

Drugdiscoveryandpersonalized medicine

14Translationalresearchin drugdiscovery:Tinystepsbefore thegiantleap347

SindhuriUpadrastaandVikasYadav*

14.1Introduction348

14.2Toolsinvolvedintranslationdrug discovery349

14.3Recentsuccessfuladvancesintranslationdrug discovery351

14.3.1Cancer352

14.3.2Diabetes355

14.3.3Acquiredimmunodeficiency syndrome355

14.3.4Autoimmunedisorders356

14.3.5Neurologicaldisorder357

14.3.6Cardiovasculardisease(CVD)357

14.4Opportunitiesintranslationdrug discovery358

14.5Challengesintranslationdrugdiscovery359

14.6Approachestoboosttranslationaldrug discovery360

14.7Conclusion364

14.8Futureperspective364 References365

15FLAGSHIP:Anoveldrugdiscovery platformoriginatingfromthe “darkmatterofthegenome”371

NeerajVerma,SiddharthManvatiandPawanDhar

15.1Introduction371

15.2Designingnoveltherapeuticpeptidesfrom darkmatterofthegenome373

15.2.1Antimicrobialpeptides373

15.2.2Antimalarialpeptides374

15.2.3Anti-Alzheimerpeptides374

15.2.4Drawbacksofpeptides therapeutics375

15.2.5Futureapplications375 15.3Pseudogenes:apotentialbiotherapeutic target376

15.3.1Pseudogene-directedgene regulation377 References377

Socio-economicimpactof translationalbiotechnology

16Roleofsharedresearchfacilities/core facilitiesintranslationalresearch383

16.1Introduction:socioeconomicimpactof translationalresearch384

16.1.1Challengesfacedintranslational research385

16.2Corefacility:sharedresearch shared cost386

16.2.1Corefacilitiesofprimesignificancein translationalresearch388

16.3Researchanddevelopmentsupporting mechanism:environmentalscan(theUnited StatesandCanada)389

16.3.1Supportingtranslationalresearch throughcorefacilitiesintheUnited States—frompasttopresent390

16.3.2Canada’secosystemoftranslational researchandfunding mechanism392

16.3.3Highlightsaroundtheworld394

16.3.4Glimpsesofglobalresearchand developmentexpenditure396

16.4Efficienciesandleanpracticesinresearch management399

16.4.1Corefacilitiesbusinessmodel399

16.4.2Governancemodelforcore facility402

16.4.3Corefacilitiesandresearch outcome402

x Contents

16.5Finalnotes:learningsforfuture403

16.5.1Integrationofcorefacilitieswithin theinstitutionalstrategicplan403

16.5.2Comprehensiveavailabilityof infrastructureinventory403

16.5.3Impactmeasurement404

Acknowledgments404 References404

17AnewTOPSIS-basedapproachto evaluatetheeconomicindicatorsinthe healthcaresystemandtheimpactof biotechnology407

PriyankaMajumderandApuKumarSaha

17.1Introduction408

17.2Techniquefororderofpreferencebysimilarity toidealsolutionapproach410

17.2.1Metricspace410

17.2.2Newtechniquefororderofpreference bysimilaritytoidealsolution approach411

17.3Methodology412

17.3.1Selectionofcriteria413

17.3.2Selectionofindicators414

17.3.3Applicationofnewtechniquefor orderofpreferencebysimilarityto idealsolutionapproach414

17.3.4Analysisofsensitivity416

17.4Resultanddiscussion416

17.4.1Resultfromtechniquefororderof preferencebysimilaritytoideal solution1416

17.4.2Resultfromtechniquefororderof preferencebysimilaritytoideal solution417

17.4.3Resultfromsensitivityanalysis418

17.5Conclusion418 References419

Glossary421 Index425

Listofcontributors

RavichandranVijayaAbinaya RenalResearch Lab,SchoolofBiosciencesandTechnology, CentreforBiomedicalResearch,Vellore InstituteofTechnology,Vellore,India

VidhuAeri DepartmentofPharmacognosy& Phytochemistry,SPER,JamiaHamdard,New Delhi,India

GunjanArora YaleUniversity,NewHaven, CT,UnitedStates

KritiArora ProteusDigitalHealth,Inc., RedwoodCity,CA,UnitedStates

RajkumarChakraborty Departmentof Biotechnology,DelhiTechnologicalUniversity, Delhi,India

SureshKumarChalapareddy National InstitutesofHealth.,Bethesda,MD,United States

NitinChaudhary DepartmentofBiosciences andBioengineering,IndianInstituteof TechnologyGuwahati,Guwahati,India

MunishChhabra MolecularAssemblies,San Diego,CA,UnitedStates

RavindreshChhabra Departmentof Biochemistry,CentralUniversityofPunjab, Bathinda,Punjab,India

DebikaDatta DepartmentofBiosciencesand Bioengineering,IndianInstituteof TechnologyGuwahati,Guwahati,India

PawanDhar SchoolofBiotechnology, JawaharlalNehruUniversity,NewDelhi India

NituDogra ProteomicsandTranslational ResearchLab,CentreforMedicalBiotechnology,AmityInstituteofBiotechnology,Amity University,Noida,India

RajanGuha NationalInstitutesofHealth., Bethesda,MD,UnitedStates

DebleenaGuin GenomicsandMolecular MedicineUnit,InstituteofGenomicsand IntegrativeBiology(IGIB),Councilof ScientificandIndustrialResearch(CSIR), Delhi,India;GNRamachandranKnowledge Centre,CouncilofScientificandIndustrial Research(CSIR)—InstituteofGenomicsand IntegrativeBiology(IGIB),Delhi,India

YashaHasija DepartmentofBiotechnology, DelhiTechnologicalUniversity,Delhi,India; DepartmentofBioinformatics,Delhi TechnologicalUniversity,Shahbad Daulatpur,MainBawanaRoad,Delhi,India

DeepshikhaPandeKatare Proteomicsand TranslationalResearchLab,Centrefor MedicalBiotechnology,AmityInstituteof Biotechnology,AmityUniversity,Noida, India

RitushreeKukreti GenomicsandMolecular MedicineUnit,InstituteofGenomicsand IntegrativeBiology(IGIB),CouncilofScientific andIndustrialResearch(CSIR),Delhi,India; AcademyofScientificandInnovative Research(AcSIR),Ghaziabad,India

YatenderKumar NetajiSubhasUniversityof Technology,Delhi,India

PriyankaMajumder DepartmentofBasic ScienceandHumanities(Mathematics), TechnoCollegeofEngineeringAgartala, Maheshkhola,Agartala,Tripura,India

RuchiJakhmolaMani Proteomicsand TranslationalResearchLab,Centrefor MedicalBiotechnology,AmityInstituteof Biotechnology,AmityUniversity,Noida, India

SiddharthManvati SchoolofBiotechnology, JawaharlalNehruUniversity,NewDelhi India

SavitaMishra ProteomicsandTranslational ResearchLab,CentreforMedical Biotechnology,AmityInstituteof Biotechnology,AmityUniversity,Noida,India

BhavanaMuralidharan BrainDevelopment andDiseaseMechanisms,inStem-Institute forStemCellScienceandRegenerative Medicine,Bangalore,India

RichaNayak DepartmentofBiotechnology, DelhiTechnologicalUniversity,Delhi,India

AjitKumarRai SystemsToxicologyand HealthRiskAssessmentGroup,CSIR-Indian InstituteofToxicologyResearch(CSIR-IITR), VishvigyanBhawan,Lucknow,India; AcademyofScientificandInnovative Research(AcSIR),Ghaziabad,India

S.Ramachandran GNRamachandran KnowledgeCentre,CouncilofScientificand IndustrialResearch(CSIR)—Instituteof GenomicsandIntegrativeBiology(IGIB),Delhi, India;AcademyofScientificandInnovative Research(AcSIR),Ghaziabad,India

SrividhyaRavichandran Departmentof Biotechnology,IndianInstituteofTechnology IIT,Chennai,India

ApuKumarSaha DepartmentofMathematics, NationalInstituteofTechnologyAgartala, Barjala,Jirania,Tripura,India

SamvednaSaini NetajiSubhasUniversityof Technology,Delhi,India

AndaleebSajid YaleUniversity,NewHaven, CT,UnitedStates

NeerajKumarSatija SystemsToxicologyand HealthRiskAssessmentGroup,CSIR-Indian InstituteofToxicologyResearch(CSIR-IITR), VishvigyanBhawan,Lucknow,India;

AcademyofScientificandInnovative Research(AcSIR),Ghaziabad,India

MritunjaySaxena ICMR-NationalInstituteof MalariaResearch,Delhi,India

VidhuSharma BCCHRCoreTechnologiesand Services,BCChildren’sHospitalResearch Institute,Vancouver,BC,Canada

PoojaSingh GenomicsandMolecular MedicineUnit,InstituteofGenomicsand IntegrativeBiology(IGIB),Councilof ScientificandIndustrialResearch(CSIR), Delhi,India;AcademyofScientificand InnovativeResearch(AcSIR),Ghaziabad, India

SaritaThakran GenomicsandMolecular MedicineUnit,InstituteofGenomicsand IntegrativeBiology(IGIB),CouncilofScientific andIndustrialResearch(CSIR),Delhi,India; AcademyofScientificandInnovative Research(AcSIR),Ghaziabad,India

SindhuriUpadrasta CSIR-NationalChemical Laboratory,Pune,India

GauravVerma ClinicalResearchCenter,Lund UniversityofDiabeticCenter,Lunds University,Lund,Sweden

NeerajVerma SchoolofBiotechnology, JawaharlalNehruUniversity,NewDelhiIndia

PragasamViswanathan RenalResearchLab, SchoolofBiosciencesandTechnology,Centre forBiomedicalResearch,VelloreInstituteof Technology,Vellore,India

VikasYadav InterdisciplinaryClusterfor AppliedGenoproteomics,Universityof Lie ` ge,Lie ` ge,Belgium;PresentAddress: ClinicalResearchCentre,LundUniversity, Malmo ¨ ,Sweden

Preface

Theadvancementsinthefieldofbiotechnologyhavebeenmonumentalandthe pacethereof,exponential.However,the sameisnotparalleledintheclinicalsetting. Thelackofadequatetranslationofbasic biomedicalresearchintoclinicalapplicationshasbeenamatterofhugeconcernfor theentireclinicalscientificcommunity. Therefore,thereisaneedtoachievecongruenceinboth,sothattheworkdonein researchlaboratoriesgetspercolatedinto thereal-timemedicalpractice.

Thisvoidhasledtotheemergenceofan excitingfieldof“benchtobedside”translationalresearch,sothatthelastmaninthe queue,thatis,thepatient,getsbenefitted. Thisbook“TranslationalBiotechnology:A journeyfromlaboratorytotheclinics”isa sincereefforttowardunderstandingthe stepsinvolvedintranslatingpath-breaking innovativeresearchandemergingscientific insightstoreachingthepatients,andinthe process,creatingnewtherapies,preventing, diagnosingandtreatingdiseases,and improvinghealthandliving.

Thebook,interalia,isaimedattransferringfundamentalbiologicaldiscoveries andtechnologiesfromtheresearchlaboratoriesintopatientcare,inthequestfor effectivehealthcare.Itattemptstotraverse thelongjourneyfrombenchworkto healthcarereformsandalsotriestoaddress theobstacles,lowsuccessrates,failures, andchallengesinthecomplexvoyage.

Inthisbook,westringtogethercontributionsfrominternationallyacclaimed authorsfromvariousdomainsofbiotechnologytoofferuniqueinsightsintheir

respectivefieldsofexpertise.Itwilltake thereadersthroughseveralfacetsoftranslationalresearchinbiotechnologywith illustrativeexamples.Theintroductorysectionsofthebookintroduceadvancedbiotechnologyprinciplesandprocessesin diseasestudies.Thissectionemphasizes technologiesthatleadtoorassistinthediscoveryofbetterclinicaloutcomes.Itis hopedthatitwillshapetheunderstanding ofcriticalprocessesintheflowfrombasic sciencestopracticalapplicationsintheclinicalsetting,viatranslationalstudiesand clinicaltrials.Thebookalsodiscussesthe advancementsindevices,biologics,vaccines,andseveralbiologicalmodalities,as anintroductiontobiotechnologyproducts thatarebeingusedintherapy.

Thesubsequentsectionsdealwithtranslationalapproachesinnewerdisciplinesof biotechnology,likebioinformatics,systems biology,andsyntheticbiology.Itdiscusses practicalapproachesinthedevelopmentof personalizedmedicine,clinicalsystems, andtranslationalmedicine.Italsooutlines futureresearchprospectsofthebenchto bedsideapproach.

Theconclusionsectionisoneofitskind thatgivesthereadersabirds-eyeviewof thesocioeconomicaspectsassociatedwith translationalbiotechnology.Thegoalisto makethereadersawareofthefeasibilityof carryingouttranslationalresearch,its availabilitytothepublic,andtheimpact causedbydiscoveriesmadeinthelaboratory.Itdiscussesthetechnologicaland monetarychallengesfacedindeveloping andunderdevelopedcountriesincarrying

outtranslationalresearch,andwaysto overcomethem.Italsodealswiththelegal andethicalaspectsoftranslational biotechnology.

Thegoalofthebookistoprovideina lucidform,theresearchinthefieldofbiotechnologythatistranslationalinnature,is cost-effective,andreadilyavailableforuse. Isincerelyhopethatthereaderswillbenefitfromthiscomprehensivebook,which willfurtherinspireandencouragethemto adoptsuchpracticesintheirresearchwork, orientedtowardclinicalapplications.

Everybookisanembodimentofcollectiveeffort.Iexpressmygratitudetoallthe contributorsfordeliveringsuchinsightful compilationsoftheirrespectiveareasof research,andthevaluableinputprovided bythereviewers.Iamindebtedtothe entireteamatElsevierforbeinginclose collaborationatvariousstagesforbringing outthisbookandensuringasmoothsailingpublicationprocess.

Another random document with no related content on Scribd:

violently with their wings, half stifling the dog with showers of spray, and half swimming, half fluttering out of his reach. Trip, no whit daunted, though becoming more and more breathless, pursued them again; and this was repeated times without number.

"Oh dear, oh dear, I know they'll kill Trip," Hecla kept saying, almost crying. "Poor little Trip. Trip, do come away. Come, Trip. I know he'll be killed!"

"It's a deal more likely he'll kill one o' the geese, and there'll be a pretty kettle o' fish to fry," declared Elisabeth. "We can't stop longer, Miss Hecla. It's time to go home, and Miss Anne told me I was to be sure to be early, 'cause it worries Miss Storey so if we ain't."

"But we can't leave Trip. We can't possibly, Elisabeth. We must wait till he comes away. He'll get killed, if we go. Just look!—" As Trip, gasping for breath, reached the flock, and with a great fluttering and splashing, the geese once more skimmed across out of his reach. "Oh, you naughty naughty Trip. I know they'll kill him! He'll drown. Oh dear!"

"He'll take care of himself—never you fear. Miss Hecla, you've got to come. I can't stop, nor let you stop, if it was a dozen Trips. I've promised Miss Anne I wouldn't be late, and I ain't going to break my word. And you've made lots of promises that you'd be good; and if you don't come, you won't be good."

Yes, Hecla knew this; and she knew now the consequences that might spring from wrong-doing. She did not forget. But it was very, very hard. Poor dear Trip looked so exhausted, and swam so heavily, and gasped so hard for breath, that she felt sure he would soon fall into the clutches of those big noisy geese, and would sink and

drown, and never rise again to the surface of the pond. And this might be her last sight of dear Trip. And Chris—what would Chris say?

But she had promised again and again. She had said she would try her very best to be good and obedient.

"Yes, I'll come," she murmured, turning her back upon the pond, and trying hard not to cry. "Please, mayn't we run very fast, and then we can send somebody to save poor little Trip?"

Elisabeth was quite willing, and they set off at full speed, each taking one of Ivy's hands to help her along.

And before they were half-way to the gate of that same field, Trip came flying cheerfully after them, none the worse for his exciting chase. So soon as he found himself alone, he left the geese, and followed his friends.

Hecla was immensely relieved, and did not know whether to scold him or to kiss him. So she did both by turns, and both had much the same effect on Trip. She was very, very glad that she had not given way to the temptation to disobey Elizabeth.

They reached "The Cottage" in good time; but the midday meal was not to be so punctual as usual that day. As they arrived at the front gate, a fly from the station drove up and stopped. And a voice cried from within,—

"Ivy! Ivy! My little darling!"

"It's mummie!" Ivy exclaimed, getting pink all over her face.

In a moment, two people were out of the cab, and Ivy was folded in her mother's tight embrace, while her father was kissing the top of her head, and trying to get hold of a little bit of his child.

Hecla stood looking on, and the two aunties came out, very much astonished.

But at first, neither Mr. nor Mrs. Croft could look at anybody or anything except their child, from whom they had been so many months parted.

Ivy's happy murmurs of "Mummie!" and "Daddy!" mingled with their smothered sounds of joy.

At last, they spoke to Aunt Millicent and Aunt Anne, Mrs. Croft still clasping Ivy, and the child still clinging to her.

"Yes, we have really, really come home," Mrs. Croft said.

"And you won't go away again, mummie?" Ivy entreated, as they went indoors, after a good deal of questioning, and of half answering, everybody speaking confusedly all at once.

"No, my sweet; never, never again, I hope!"

They had still to explain how it was that they had returned. It was Ivy who made them do so. Her little voice was heard very distinctly enquiring:

"Why-because have mummie and daddy got back?"

"Sweet little 'why-because!' I am so glad you have not cured her of that," Mrs. Croft said, as she hugged her child afresh.

Then she and her husband thanked Miss Storey and Miss Anne with all their hearts for taking such care of Ivy. She looked so well, they said; so rosy and strong and healthy and happy.

And then they explained "why-because" this had come about. Ivy's daddy had been ill, and the doctor had said that he ought not to stay in Africa. And they had been very much puzzled what to do, for it had been an expensive voyage out, and they did not see how they could afford to return so soon. And while they were wondering what to do, an old uncle had died suddenly; and this kind old uncle left them some money. And that had made it easy for them to give up Africa, and to come back to dear old England.

"But will Ivy have to go away from here?" asked Hecla in dismay. "I do hope she won't. I want Ivy always."

It would indeed have been a great trouble to both the children, had they been separated. Very soon, however, they found to their delight that this was not to be. Mr. and Mrs. Croft wanted to have Hecla with them—always. They meant to take a house at Nortonbury, as near as possible to the Miss Storeys, and to live there; and they wished to bring up Hecla with Ivy, because it was not good for Ivy to be an only child. They feared that their darling might be too much indulged, and spoilt.

Miss Anne was grieved at the thought of losing both the children; yet she knew that it was better so. And she perhaps felt a little relieved too. For Miss Storey was not strong enough, since the river accident, to stand children constantly about; and Miss Anne wanted to be free to devote herself more entirely to her elder sister.

Besides, if Mr. and Mrs. Croft lived near, the children would be perpetually running in and out; and that would keep the aunts cheerful.

And was it not curious? Aunt Anne knew of a nice, pretty house, just the right size, with a garden, standing empty round the next corner.

Mr. Croft went off to see it directly after dinner. And he liked the house and the garden so much, that in a few days everything was settled.

So, though Hecla would no longer be all day long with Miss Storey and Miss Anne, she would be less than five minutes off. Ivy was delighted to have her dear Hecla with her in the new home. And Mr. and Mrs. Croft were so good, and kind, and gentle with her, that very soon it almost felt to Hecla like the days when she had her own mother and father.

"Mummie, why-because does Hecla kiss you so very, very much?" Ivy one day asked.

"I suppose, pet, it is because she is a tender-hearted little girl, and likes to be loved," Mrs. Croft replied. "And she is very fond of Ivy too, I am sure—isn't she?"

"And I do love Hecla, mummie. I love her—heaps. And p'rhaps that's why-because she loves me," Ivy suggested, in her serious fashion.

THE

END

LONDON: PRINTED BY WILLIAM CLOWES AND SONS, LIMITED.

*** END OF THE PROJECT GUTENBERG EBOOK LITTLE "WHYBECAUSE" ***

Updated editions will replace the previous one—the old editions will be renamed.

Creating the works from print editions not protected by U.S. copyright law means that no one owns a United States copyright in these works, so the Foundation (and you!) can copy and distribute it in the United States without permission and without paying copyright royalties. Special rules, set forth in the General Terms of Use part of this license, apply to copying and distributing Project Gutenberg™ electronic works to protect the PROJECT GUTENBERG™ concept and trademark. Project Gutenberg is a registered trademark, and may not be used if you charge for an eBook, except by following the terms of the trademark license, including paying royalties for use of the Project Gutenberg trademark. If you do not charge anything for copies of this eBook, complying with the trademark license is very easy. You may use this eBook for nearly any purpose such as creation of derivative works, reports, performances and research. Project Gutenberg eBooks may be modified and printed and given away—you may do practically ANYTHING in the United States with eBooks not protected by U.S. copyright law. Redistribution is subject to the trademark license, especially commercial redistribution.

START: FULL LICENSE

THE FULL PROJECT GUTENBERG LICENSE

PLEASE READ THIS BEFORE YOU DISTRIBUTE OR USE THIS WORK

To protect the Project Gutenberg™ mission of promoting the free distribution of electronic works, by using or distributing this work (or any other work associated in any way with the phrase “Project Gutenberg”), you agree to comply with all the terms of the Full Project Gutenberg™ License available with this file or online at www.gutenberg.org/license.

Section 1. General Terms of Use and Redistributing Project Gutenberg™ electronic works

1.A. By reading or using any part of this Project Gutenberg™ electronic work, you indicate that you have read, understand, agree to and accept all the terms of this license and intellectual property (trademark/copyright) agreement. If you do not agree to abide by all the terms of this agreement, you must cease using and return or destroy all copies of Project Gutenberg™ electronic works in your possession. If you paid a fee for obtaining a copy of or access to a Project Gutenberg™ electronic work and you do not agree to be bound by the terms of this agreement, you may obtain a refund from the person or entity to whom you paid the fee as set forth in paragraph 1.E.8.

1.B. “Project Gutenberg” is a registered trademark. It may only be used on or associated in any way with an electronic work by people who agree to be bound by the terms of this agreement. There are a few things that you can do with most Project Gutenberg™ electronic works even without complying with the full terms of this agreement. See paragraph 1.C below. There are a lot of things you can do with Project Gutenberg™ electronic works if you follow the terms of this agreement and help preserve free future access to Project Gutenberg™ electronic works. See paragraph 1.E below.

1.C. The Project Gutenberg Literary Archive Foundation (“the Foundation” or PGLAF), owns a compilation copyright in the collection of Project Gutenberg™ electronic works. Nearly all the individual works in the collection are in the public domain in the United States. If an individual work is unprotected by copyright law in the United States and you are located in the United States, we do not claim a right to prevent you from copying, distributing, performing, displaying or creating derivative works based on the work as long as all references to Project Gutenberg are removed. Of course, we hope that you will support the Project Gutenberg™ mission of promoting free access to electronic works by freely sharing Project Gutenberg™ works in compliance with the terms of this agreement for keeping the Project Gutenberg™ name associated with the work. You can easily comply with the terms of this agreement by keeping this work in the same format with its attached full Project Gutenberg™ License when you share it without charge with others.

1.D. The copyright laws of the place where you are located also govern what you can do with this work. Copyright laws in most countries are in a constant state of change. If you are outside the United States, check the laws of your country in addition to the terms of this agreement before downloading, copying, displaying, performing, distributing or creating derivative works based on this work or any other Project Gutenberg™ work. The Foundation makes no representations concerning the copyright status of any work in any country other than the United States.

1.E. Unless you have removed all references to Project Gutenberg:

1.E.1. The following sentence, with active links to, or other immediate access to, the full Project Gutenberg™ License must appear prominently whenever any copy of a Project Gutenberg™ work (any work on which the phrase “Project Gutenberg” appears, or with which the phrase “Project Gutenberg” is associated) is accessed, displayed, performed, viewed, copied or distributed:

This eBook is for the use of anyone anywhere in the United States and most other parts of the world at no cost and with almost no restrictions whatsoever. You may copy it, give it away or re-use it under the terms of the Project Gutenberg License included with this eBook or online at www.gutenberg.org. If you are not located in the United States, you will have to check the laws of the country where you are located before using this eBook.

1.E.2. If an individual Project Gutenberg™ electronic work is derived from texts not protected by U.S. copyright law (does not contain a notice indicating that it is posted with permission of the copyright holder), the work can be copied and distributed to anyone in the United States without paying any fees or charges. If you are redistributing or providing access to a work with the phrase “Project Gutenberg” associated with or appearing on the work, you must comply either with the requirements of paragraphs 1.E.1 through 1.E.7 or obtain permission for the use of the work and the Project Gutenberg™ trademark as set forth in paragraphs 1.E.8 or 1.E.9.

1.E.3. If an individual Project Gutenberg™ electronic work is posted with the permission of the copyright holder, your use and distribution must comply with both paragraphs 1.E.1 through 1.E.7 and any additional terms imposed by the copyright holder. Additional terms will be linked to the Project Gutenberg™ License for all works posted with the permission of the copyright holder found at the beginning of this work.

1.E.4. Do not unlink or detach or remove the full Project Gutenberg™ License terms from this work, or any files containing a part of this work or any other work associated with Project Gutenberg™.

1.E.5. Do not copy, display, perform, distribute or redistribute this electronic work, or any part of this electronic work, without prominently displaying the sentence set forth in paragraph 1.E.1

with active links or immediate access to the full terms of the Project Gutenberg™ License.

1.E.6. You may convert to and distribute this work in any binary, compressed, marked up, nonproprietary or proprietary form, including any word processing or hypertext form. However, if you provide access to or distribute copies of a Project Gutenberg™ work in a format other than “Plain Vanilla ASCII” or other format used in the official version posted on the official Project Gutenberg™ website (www.gutenberg.org), you must, at no additional cost, fee or expense to the user, provide a copy, a means of exporting a copy, or a means of obtaining a copy upon request, of the work in its original “Plain Vanilla ASCII” or other form. Any alternate format must include the full Project Gutenberg™ License as specified in paragraph 1.E.1.

1.E.7. Do not charge a fee for access to, viewing, displaying, performing, copying or distributing any Project Gutenberg™ works unless you comply with paragraph 1.E.8 or 1.E.9.

1.E.8. You may charge a reasonable fee for copies of or providing access to or distributing Project Gutenberg™ electronic works provided that:

• You pay a royalty fee of 20% of the gross profits you derive from the use of Project Gutenberg™ works calculated using the method you already use to calculate your applicable taxes. The fee is owed to the owner of the Project Gutenberg™ trademark, but he has agreed to donate royalties under this paragraph to the Project Gutenberg Literary Archive Foundation. Royalty payments must be paid within 60 days following each date on which you prepare (or are legally required to prepare) your periodic tax returns. Royalty payments should be clearly marked as such and sent to the Project Gutenberg Literary Archive Foundation at the address specified in Section 4, “Information

about donations to the Project Gutenberg Literary Archive Foundation.”

• You provide a full refund of any money paid by a user who notifies you in writing (or by e-mail) within 30 days of receipt that s/he does not agree to the terms of the full Project Gutenberg™ License. You must require such a user to return or destroy all copies of the works possessed in a physical medium and discontinue all use of and all access to other copies of Project Gutenberg™ works.

• You provide, in accordance with paragraph 1.F.3, a full refund of any money paid for a work or a replacement copy, if a defect in the electronic work is discovered and reported to you within 90 days of receipt of the work.

• You comply with all other terms of this agreement for free distribution of Project Gutenberg™ works.

1.E.9. If you wish to charge a fee or distribute a Project Gutenberg™ electronic work or group of works on different terms than are set forth in this agreement, you must obtain permission in writing from the Project Gutenberg Literary Archive Foundation, the manager of the Project Gutenberg™ trademark. Contact the Foundation as set forth in Section 3 below.

1.F.

1.F.1. Project Gutenberg volunteers and employees expend considerable effort to identify, do copyright research on, transcribe and proofread works not protected by U.S. copyright law in creating the Project Gutenberg™ collection. Despite these efforts, Project Gutenberg™ electronic works, and the medium on which they may be stored, may contain “Defects,” such as, but not limited to, incomplete, inaccurate or corrupt data, transcription errors, a copyright or other intellectual property infringement, a defective or

damaged disk or other medium, a computer virus, or computer codes that damage or cannot be read by your equipment.

1.F.2. LIMITED WARRANTY, DISCLAIMER OF DAMAGES - Except for the “Right of Replacement or Refund” described in paragraph 1.F.3, the Project Gutenberg Literary Archive Foundation, the owner of the Project Gutenberg™ trademark, and any other party distributing a Project Gutenberg™ electronic work under this agreement, disclaim all liability to you for damages, costs and expenses, including legal fees. YOU AGREE THAT YOU HAVE NO REMEDIES FOR NEGLIGENCE, STRICT LIABILITY, BREACH OF WARRANTY OR BREACH OF CONTRACT EXCEPT THOSE PROVIDED IN PARAGRAPH

1.F.3. YOU AGREE THAT THE FOUNDATION, THE TRADEMARK OWNER, AND ANY DISTRIBUTOR UNDER THIS AGREEMENT WILL NOT BE LIABLE TO YOU FOR ACTUAL, DIRECT, INDIRECT, CONSEQUENTIAL, PUNITIVE OR INCIDENTAL DAMAGES EVEN IF YOU GIVE NOTICE OF THE POSSIBILITY OF SUCH DAMAGE.

1.F.3. LIMITED RIGHT OF REPLACEMENT OR REFUND - If you discover a defect in this electronic work within 90 days of receiving it, you can receive a refund of the money (if any) you paid for it by sending a written explanation to the person you received the work from. If you received the work on a physical medium, you must return the medium with your written explanation. The person or entity that provided you with the defective work may elect to provide a replacement copy in lieu of a refund. If you received the work electronically, the person or entity providing it to you may choose to give you a second opportunity to receive the work electronically in lieu of a refund. If the second copy is also defective, you may demand a refund in writing without further opportunities to fix the problem.

1.F.4. Except for the limited right of replacement or refund set forth in paragraph 1.F.3, this work is provided to you ‘AS-IS’, WITH NO OTHER WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED,

INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PURPOSE.

1.F.5. Some states do not allow disclaimers of certain implied warranties or the exclusion or limitation of certain types of damages. If any disclaimer or limitation set forth in this agreement violates the law of the state applicable to this agreement, the agreement shall be interpreted to make the maximum disclaimer or limitation permitted by the applicable state law. The invalidity or unenforceability of any provision of this agreement shall not void the remaining provisions.

1.F.6. INDEMNITY - You agree to indemnify and hold the Foundation, the trademark owner, any agent or employee of the Foundation, anyone providing copies of Project Gutenberg™ electronic works in accordance with this agreement, and any volunteers associated with the production, promotion and distribution of Project Gutenberg™ electronic works, harmless from all liability, costs and expenses, including legal fees, that arise directly or indirectly from any of the following which you do or cause to occur: (a) distribution of this or any Project Gutenberg™ work, (b) alteration, modification, or additions or deletions to any Project Gutenberg™ work, and (c) any Defect you cause.

Section 2. Information about the Mission of Project Gutenberg™

Project Gutenberg™ is synonymous with the free distribution of electronic works in formats readable by the widest variety of computers including obsolete, old, middle-aged and new computers. It exists because of the efforts of hundreds of volunteers and donations from people in all walks of life.

Volunteers and financial support to provide volunteers with the assistance they need are critical to reaching Project Gutenberg™’s goals and ensuring that the Project Gutenberg™ collection will

remain freely available for generations to come. In 2001, the Project Gutenberg Literary Archive Foundation was created to provide a secure and permanent future for Project Gutenberg™ and future generations. To learn more about the Project Gutenberg Literary Archive Foundation and how your efforts and donations can help, see Sections 3 and 4 and the Foundation information page at www.gutenberg.org.

Section 3. Information about the Project Gutenberg Literary Archive Foundation

The Project Gutenberg Literary Archive Foundation is a non-profit 501(c)(3) educational corporation organized under the laws of the state of Mississippi and granted tax exempt status by the Internal Revenue Service. The Foundation’s EIN or federal tax identification number is 64-6221541. Contributions to the Project Gutenberg Literary Archive Foundation are tax deductible to the full extent permitted by U.S. federal laws and your state’s laws.

The Foundation’s business office is located at 809 North 1500 West, Salt Lake City, UT 84116, (801) 596-1887. Email contact links and up to date contact information can be found at the Foundation’s website and official page at www.gutenberg.org/contact

Section 4. Information about Donations to the Project Gutenberg Literary Archive Foundation

Project Gutenberg™ depends upon and cannot survive without widespread public support and donations to carry out its mission of increasing the number of public domain and licensed works that can be freely distributed in machine-readable form accessible by the widest array of equipment including outdated equipment. Many

small donations ($1 to $5,000) are particularly important to maintaining tax exempt status with the IRS.

The Foundation is committed to complying with the laws regulating charities and charitable donations in all 50 states of the United States. Compliance requirements are not uniform and it takes a considerable effort, much paperwork and many fees to meet and keep up with these requirements. We do not solicit donations in locations where we have not received written confirmation of compliance. To SEND DONATIONS or determine the status of compliance for any particular state visit www.gutenberg.org/donate.

While we cannot and do not solicit contributions from states where we have not met the solicitation requirements, we know of no prohibition against accepting unsolicited donations from donors in such states who approach us with offers to donate.

International donations are gratefully accepted, but we cannot make any statements concerning tax treatment of donations received from outside the United States. U.S. laws alone swamp our small staff.

Please check the Project Gutenberg web pages for current donation methods and addresses. Donations are accepted in a number of other ways including checks, online payments and credit card donations. To donate, please visit: www.gutenberg.org/donate.

Section 5. General Information About Project Gutenberg™ electronic works

Professor Michael S. Hart was the originator of the Project Gutenberg™ concept of a library of electronic works that could be freely shared with anyone. For forty years, he produced and distributed Project Gutenberg™ eBooks with only a loose network of volunteer support.

Project Gutenberg™ eBooks are often created from several printed editions, all of which are confirmed as not protected by copyright in the U.S. unless a copyright notice is included. Thus, we do not necessarily keep eBooks in compliance with any particular paper edition.

Most people start at our website which has the main PG search facility: www.gutenberg.org.

This website includes information about Project Gutenberg™, including how to make donations to the Project Gutenberg Literary Archive Foundation, how to help produce our new eBooks, and how to subscribe to our email newsletter to hear about new eBooks.

Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.
Download ebooks file Translational biotechnology : a journey from laboratory to clinics. 1st edition by Education Libraries - Issuu